Tools
Stock profile

BIOGEN INC. (BIIB)

BIIB · Latest close $251.41 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$251.41
As of Nov 18, 2026
Tracked funds holding
5 of 149
2026 Q2 13F filings
Opened / added
1 / 0
vs previous quarter
Trimmed / exited
3
vs previous quarter

BIOGEN INC. (BIIB) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions and 3 funds trimming or exiting versus the previous quarter. 2 members of Congress reported 4 purchases vs 3 sales. Latest close $251.41 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Congress
4 buys vs 3 sales
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Hillman Capital Management · Patient Capital Management · Perceptive Advisors — 5 tracked funds hold BIIB. See all holders.

Insider and Congress activity

2 members of Congress reported buying (4 purchases vs 3 sales). Latest buy: Jun 5, 2026. Politician trading

Often held alongside

BOSTON SCIENTIFIC CORP (BSX) · AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · Immunovant, Inc. (IMVT) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Hillman Capital Management3.75%23,993TRIMMED (-18.8%) Q3 filed Nov 16
Patient Capital Management2.01%283,697TRIMMED (-25.3%) Q3 filed Nov 12
Perceptive Advisors0.90%276,173NEW Q3 filed Nov 16
Causeway Capital Management0.65%278,283TRIMMED (-0.9%) Q3 filed Nov 13
OrbiMed Advisors0.25%61,600HELD Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +19.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

254.87107.722024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding1,045 of 8,857 filers
Long-only filers among them1,035
Change vs 2026 Q1+57 net · 942 entered · 885 exited
Shares reported, all filers140,647,629
Reported value, all filers$30.6B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryBiological Products, (No Diagnostic Substances) (SIC 2836)
Revenue · FY2025$9.9B
Net income · FY2025$1.3B
Total assets · FY2025$29.4B
Shares outstanding147,820,223
Market cap (at latest close)$37.2B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 26, 2026.

Short interest

Shares short · Oct 15, 20265,500,386
Share of shares outstanding3.72%
Days to cover4.39

Shares short at recent settlements — Jul 31, 2026: 5.5M · Aug 14, 2026: 5.2M · Aug 31, 2026: 5.7M · Sep 15, 2026: 5.8M · Sep 30, 2026: 6.0M · Oct 15, 2026: 5.5M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 26, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20262,091
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 2026<0.1%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 2K.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 26, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Aug 4, 2026Minor LloydDirector593$119.2KAug 4, 2026SEC filing
Aug 3, 2026Minor LloydDirector593$120.6KAug 3, 2026SEC filing
Feb 9, 2026Singhal PriyaOfficer2,660$531.5KFeb 9, 2026SEC filing
Feb 2, 2026Singhal PriyaOfficer748$134.1KFeb 2, 2026SEC filing
Sep 2, 2025Singhal PriyaOfficer517$69.0KSep 2, 2025SEC filing
Jul 8, 2025Izzar RachidOfficer2,223$300.1KJul 8, 2025SEC filing
May 19, 2025Singhal PriyaOfficer3,806$480.5KMay 19, 2025SEC filing
Mar 7, 2025STEPHEN A SHERWINDirector8,760$1.3MMar 7, 2025SEC filing
Dec 9, 2024Singhal PriyaOfficer110$17.3KDec 9, 2024SEC filing
Sep 3, 2024Singhal PriyaOfficer431$88.0KSep 3, 2024SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 6, 2026FMR LLCSC 13G/A18,294,523.5112.4%Jun 30, 2026SEC filing
Jun 5, 2026FMR LLCSC 13G/A16,652,974.8211.3%May 29, 2026SEC filing
May 6, 2026FMR LLCSC 13G/A12,807,541.58.7%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G10,989,5627.5%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 5, 2026FMR LLCSC 13G9,413,062.036.4%Dec 31, 2025SEC filing
Nov 13, 2025PRIMECAP MANAGEMENT CO/CA/SC 13G/A14,954,69710.2%Sep 30, 2025SEC filing
Nov 10, 2025STATE STREET CORPORATIONSC 13G7,321,1685.0%Sep 30, 2025SEC filing
Apr 17, 2025BlackRock, Inc.SC 13G/A12,506,6818.5%Mar 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

2 members of Congress reported buying (4 purchases vs 3 sales). Bought by Democrats and Republicans. Latest buy: Jun 5, 2026.

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Salazar, Maria ElviraHouseR32Sep 24, 2026$1,001 - $15,000
Hern, KevinHouseR01Aug 18, 2026$1,001 - $15,000
Cisneros, GilbertHouseD10Jun 5, 2026$1,001 - $15,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 222 Lobbying Disclosure Act filings named this company as client, 2000–2026; most common issues: Health Issues (156), Medicare/Medicaid (153), Taxation/Internal Revenue Code (68).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Politicians

· Bought by Members — Last 6 months: bought by a member of the U.S. Congress

· Bought by Both Parties — Last 6 months: bought by both Democratic and Republican members

Financial Screens

· Graham — Sound finances and a long run of profits

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Gross Profitability (Novy-Marx) — High gross profit relative to total assets

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Graham — Current ratio: 2.68 · Straight profitable years: 19 · Debt ratio: 0.61 · Latest net income: $1.3B

· Cash Flow (FCF) — Latest FCF: $2.1B · FCF yield: 5.6% · Positive FCF years: 3

· Gross Profitability (Novy-Marx) — Gross profit / assets: 47.3% · Gross margin: 86.6%

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.60 · Operating cash flow: $2.2B · Net income: $1.3B

· Bought by Members — Members buying: 2 · Buy txns: 4 · Sell txns: 3 · Latest buy: Jun 5, 2026

· Bought by Both Parties — Members buying: 2 · Buy txns: 4 · Sell txns: 3 · Latest buy: Jun 5, 2026

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2026 Q2, ranked #11 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together560.0%+11.4%+3.5%+7.9%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold BIIB — ranked by lift, the co-holding pattern described in Methodology: BOSTON SCIENTIFIC CORP (BSX) · AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · Immunovant, Inc. (IMVT) · REPLIGEN CORP (RGEN) · BIO-TECHNE Corp (TECH) · Vaxcyte, Inc. (PCVX).

7 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Filings audit: every filing lens on BIOGEN INC. (BIIB), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Oct 28, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jul 29, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jul 1, 20262.02 Results of Operations and Financial ConditionSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

BOSTON SCIENTIFIC CORP (BSX) · Filings audit: every filing lens on BIOGEN INC. (BIIB), scored · Practice timing on BIIB

One email a week: the week’s new filings and research. Subscribe free

← BIDU  ·  BIL →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.